Sepsis-related outcomes of patients with Philadelphia-negative myeloproliferative neoplasms
Recommended Citation
Gonzalez-Mosquera LF, Moscoso B, Tobar P, Cardenas-Maldonado D, Podrumar AI, Mesa R, and Cuenca JA. Sepsis-related outcomes of patients with Philadelphia-negative myeloproliferative neoplasms. Cancer Invest 2023; 1-20.
Document Type
Article
Publication Date
3-2-2023
Publication Title
Cancer investigation
Abstract
We analyzed the National Inpatient Sample (NIS) database to study the sepsis-related outcomes in patients with Philadelphia negative myeloproliferative neoplasms (MPN). A total of 82,087 patients were included, most had essential thrombocytosis (83.7%), followed by polycythemia vera (13.7%), and primary myelofibrosis (2.6%). Sepsis was diagnosed in 15,789 (19.2%) patients and their mortality rate was higher than non-septic patients (7.5% vs 1.8%; P<.001). Sepsis was the most significant risk factor of mortality (aOR, 3.84; 95% CI, 3.51-4.21), others included liver disease (aOR, 2.42; 95% CI, 2.11-2.78), pulmonary embolism (aOR, 2.26; 95% CI, 1.83-2.80), cerebrovascular disease (aOR, 2.05; 95% CI, 1.81-2.33), and myocardial infarction (aOR, 1.73; 95% CI, 1.52-1.96).
PubMed ID
36862101
ePublication
ePub ahead of print
First Page
1
Last Page
20
